CHARLES RIVER LABORATORIES, INC.

Charles River Laboratories has integrated Akadeum Life Sciences' GMP-grade Human T Cell Leukopak Isolation Kit into its Cell Therapy Flex Program to enhance CAR-T and TCR-T therapy manufacturing.

Charles River Laboratories has joined the EASYGEN Consortium, a European Union-backed initiative aimed at developing fully automated, hospital-based CAR-T cell therapy manufacturing within 24 hours.

Centivax raised an oversubscribed $45 million Series A round led by Future Ventures to advance its universal flu vaccine through Phase I clinical trials beginning within eight months.

Liminatus Pharma's IBA101, a second-generation CD47 inhibitor, demonstrated strong safety profile in primate studies with no observed anemia or thrombocytopenia at doses up to 100 mg/kg/week.

Resonant Clinical Solutions, a global provider of clinical trial services, has appointed Dr. Christophe Berthoux as Chief Executive Officer effective immediately.

Akadeum Life Sciences closed a $20 million+ financing round led by Michigan Capital Network to scale commercial operations and support customers entering clinical trials.

• Dr. Aidan Synnott, former Corporate VP at Charles River Laboratories with over 20 years of biomedical research experience, has been appointed CEO of Oncodesign Services to enhance client collaboration and scientific quality. • The appointment marks a significant milestone in Oncodesign's transformation following its acquisition of ZoBio and expansion into molecular radiotherapy and protein sciences. • Synnott will focus on aligning the company's structure with drug discovery priorities, integrating operations across Europe and North America, and creating a unified offering to accelerate client programs.

• FibroBiologics has unveiled a new 10,000-square-foot laboratory facility in Houston that will bring manufacturing operations in-house and accelerate development of fibroblast-based therapeutics for chronic diseases. • The expanded facility will increase the company's research capabilities, reduce reliance on external partners like Charles River Laboratories, and enable FibroBiologics to streamline its supply chain for cell therapy products. • With 240+ patents issued and pending, FibroBiologics plans to hire additional researchers to support its growing pipeline of candidates targeting multiple chronic disease indications using its proprietary fibroblast technology.

Despite market challenges, the cell and gene therapy (CGT) sector saw investments reach $15.2 billion in 2024, marking a 30% increase from the previous year, with approximately 3,000 developers and 2,000 clinical trials currently active.

Charles River Laboratories and Valo Health have identified a promising drug candidate for lupus and other autoimmune diseases using their AI-powered Logica platform, marking a significant milestone in computational drug discovery.